Trials / Completed
CompletedNCT02684799
Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination
A Phase 1, Single and Multiple-Dose, Open-Label Study in Healthy Subjects to Assess the Effect of the Acid Reducing Agents, Omeprazole (OME) and Famotidine (FAM), on the Pharmacokinetics (PK) of Cenicriviroc Mesylate (CVC)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Tobira Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This is a Phase 1, Single and Multiple-Dose, Open-Label Study in Healthy Subjects to Assess the Effect of the Acid Reducing Agents, Omeprazole and Famotidine, on the PK of CVC
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cenicriviroc | |
| DRUG | Omeprazole | |
| DRUG | Famotidine |
Timeline
- Start date
- 2016-01-31
- Primary completion
- 2016-04-11
- Completion
- 2016-04-11
- First posted
- 2016-02-18
- Last updated
- 2017-11-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02684799. Inclusion in this directory is not an endorsement.